AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has made changes in its board membership and on its management team. The company announced that Haohan Xu has been appointed as a director of the board of directors (the “Board”); he will also serve as board cochair and co-CEO. Xiaoyu Li has been named a director of the board and chief financial officer. Tianruo (Robert) Pu has also been named as a director of the board as well as chair of the audit committee and a member of the compensation committee as well as the nominating and corporate governance committee. Zhigang (Frank) Zhao will serve as a director of the board, chair of the compensation committee and a member of both the audit committee and the nominating and corporate governance committee. Honggang (Harvey) Tian has been named a director of the board as well as chair of the nominating and corporate governance committee and a member of the audit committee and compensation committee. In addition to these new appointments, the company announced that Chris Chang Yu, Jinqiu Tang, Xing Pu, Ren Luo, Jianhua Shao and Guo Feng will resign as directors of the board and/or officers of the company; Chang Yu will continue to manage AnPac’s cancer-screening technology development. The company anticipates these changes will become effective this month following the completion of customary onboarding processes required filings with the Registry of Corporate Affairs in the British Virgin Islands. “We are delighted to welcome Mr. Haohan Xu, Ms. Xiaoyu Li, Mr. Tianruo Pu, Mr. Zhigang Zhao and Mr. Honggang Tian to the board and management team,” said AnPac cochair of the board and co-CEO Dr. Chris Yu in the press release. “We believe their experience and expertise will provide significant value to AnPac Bio as we continue to explore growth opportunities in our early cancer screening and detection business and explore strategic alternatives to further unlock value for shareholders. On behalf of the board, I would also like to express my sincere gratitude to the departing directors for their incredible contribution to the company during their tenure on the board and wish them well for the future.”
To view the full press release, visit https://ibn.fm/ZUD4Y
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2022. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multicancer screening and detection-test sample volume, accumulative to January 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
